Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: LT who wrote (1473)	6/20/1998 1:58:00 AM
From: Prospector	Read Replies (1) \| Respond to of 5402

Dr Drees asked me to post this. As I read it, it shows that this blood substitute HemAssist is made of Outdated Human Blood, Availiabilty: short supply.. other information : est Production cost to eqiv dose $100 - $150 Sanguine est Production cost tp equiv dose $15 - $30 Prospector ( doesn't cut it)

To: LT who wrote (1473)	6/20/1998 9:15:00 AM
From: Jim B	Read Replies (1) \| Respond to of 5402

what?? how does that relate to SGNC?? anything that has to do with blood substitutes HAS EVERYTHING to do with SGNC.. the more info either about SGNC or its field of study the better.. no flame.. just didn't get why you didn't see the relevance.. take care. jim

To: LT who wrote (1473)	6/20/1998 10:37:00 AM
From: drdan	Read Replies (1) \| Respond to of 5402

Baxter,who seem to be very focused on bringing a "blood substitute" to market,now have no product and have spent a ton of money to find this out ....it MAY be that they will look at products already in various phases of testing rather than start from scratch, and pher02 happens to be one such product, with a bit of promise, I might add.....Sanguine has a good bit of leverage when it comes to dealing with these large companies, IMO, because they are one of the few companies left with a product that has a good chance of approval and widespread use...

To: LT who wrote (1473)	6/20/1998 10:56:00 AM
From: Mike Ankley	Read Replies (1) \| Respond to of 5402

Hi LT: Posts have been made here on SGNC pointing out that Dr. Drees has stated that synthetic blood that was derived from real blood (human, cow, etc.) would have a very difficult time becoming a viable product. This being due to a natural reaction in one's body that would cause rejection in a large enough percentage of subjects that these hemoglobin based products would never be considered safe enough, but also the difficulty in long term storage of hemoglobin based blood and also in problems with sterilizing it. Based on the above, it has also been pointed out that Sanguine's competitors that have tried for synthetic blood through this route have been dropping by the wayside. Now here is an article in the WSJ that supports that for at least 1 of the would-be competitiors of SGNC. So to me, this relates to SGNC in a big way. It backs up Dr. Drees claims about the problems of hemoglobin based products and it backs up the claims that SGNC's competition is dwindling. It has been pointed out in another post that SGNC's competition is down to 2 others, and each of them are having their own problems: techstocks.com so that potentially leaves just SGNC alone to a huge (20 billion per year) market! Cheers Mike